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Genomicinstabilityplaysacrucialroleinoncogenesis.Somaticallyacquiredmutationscandisablesomegenesandinappropriately
activate others. In addition, chromosomal rearrangements can amplify, delete, or even fuse genes, altering their functions and
contributing to malignant phenotypes. Using array comparative genomic hybridization (aCGH), a technique to detect numeric
variations between diﬀerent DNA samples, we examined genomes from zebraﬁsh (Danio rerio) T-cell leukemias of three cancer-
prone lines. In all malignancies tested, we identiﬁed recurring ampliﬁcations of a zebraﬁsh endogenous retrovirus. This retrovirus,
ZFERV, was ﬁrst identiﬁed due to high expression of proviral transcripts in thymic tissue from larval and adult ﬁsh. We conﬁrmed
ZFERV ampliﬁcations by quantitative PCR analyses of DNA from wild-type ﬁsh tissue and normal and malignant D. rerio T
cells. We also quantiﬁed ZFERV RNA expression and found that normal and neoplastic T cells both produce retrovirally encoded
transcripts, but most cancers show dramatically increased transcription. In aggregate, these data imply that ZFERV ampliﬁcation
and transcription may be related to T-cell leukemogenesis. Based on these data and ZFERV’s phylogenetic relation to viruses of the
murine-leukemia-related virus class of gammaretroviridae, we posit that ZFERV may be oncogenic via an insertional mutagenesis
mechanism.
1.Introduction
Zebraﬁsh are an emerging animal model for the study of
lymphocytic cancers. A landmark 2003 study ﬁrst described
that transgenic murine Myc (mMyc) misexpression could
induce D. rerio T-cell acute lymphoblastic leukemia (T-ALL)
[1]. Since that initial report, several other zebraﬁsh ALL
modelshavebeendescribed,utilizingtransgenicmammalian
TEL-AML1 (human), NOTCH1 (human), MYC (murine
and human), and AKT2 (murine) in similar fashion [2–5].
In addition, we used a phenotypic mutagenesis screen to
create three further zebraﬁsh models with heritable T-ALL
predisposition [6]. All but one of the eight lines cited above
are prone to T-ALL, not B-cell-lineage cancers. Like human
T-ALL, D. rerio T-ALL often arises in or spreads to the
thymus and forms tumors. Hence, these seven zebraﬁsh
lines actually more accurately model two related lymphocyte
malignancies, T-ALL and T-cell lymphoblastic lymphoma
(T-LBL). In fact, mMyc zebraﬁsh have even been used
to investigate the molecular changes that accompany the
transition between T-LBL and T-ALL [7].
Because the molecular origins of T-ALL and T-LBL are
not completely understood, these zebraﬁsh models provide
opportunities to investigate the genetic underpinnings of
these diseases’ oncogenesis. In addition, they also facilitate
inquiries designed to reveal features associated with T-ALL
and T-LBL progression. For example, in the aforementioned
study, Feng et al. demonstrated that changes in BCL2, S1P1,
and ICAM1 expression were linked to autophagy, intercellu-
lar adhesion, and intravascular invasion, thereby governing
the T-LBL to T-ALL transition [7]. Similarly, Gutierrez et al.
used transgenic zebraﬁsh T-ALL to study the dependence of2 Advances in Hematology
MYC-driven cancers upon Pten and Akt for disease persist-
ence and progression [5].
While these two studies utilized D. rerio models to
investigate candidate genes of suspected importance to
disease progression, zebraﬁsh T-cell cancers can also serve
as a means for candidate gene discovery. In our own work,
we utilized serial allo-transplantation of D. rerio T-ALL
as an experimental approach to model clinically aggressive
neoplasia[8].Similarstrategieshavebeenemployedbyother
groups, using serially allo-grafted murine T-cell lymphomas
or xeno-transplanted human T-ALL into immunodeﬁcient
mice [9, 10]. In our study, we performed aCGH to seek
acquired genomic changes common to serially passaged
D. rerio T-ALL and refractory/relapsed human T-ALL.
Several candidate genes met this criterion, including C7orf60
(zebraﬁsh homologue, zgc: 153606), a gene whose ampliﬁca-
tions were linked to both accelerated T-ALL progression in
ﬁsh and inferior outcomes in human T-ALL patients [8].
Although our study concentrated on acquired copy
number aberrations (CNAs) shared by zebraﬁsh and human
T-ALL, we also identiﬁed other genomic ampliﬁcations and
deletions seen only in D. rerio cancers. Amongst these, two
recurring copy number gains were observed in every sample,
and with further scrutiny we found that both regions cor-
responded to the same endogenous retrovirus (ERV). This
genomically integrated provirus is predicted to have 2–4
integration sites in the zebraﬁsh genome [11], and its
ploidy and genomic positions may vary between individual
animals, complicating its inquiry. In this paper, we use two
independent methodologies to show that this multicopy
ERV undergoes further ampliﬁcation in both normal and
neoplastic zebraﬁsh T cells, which could create new and
potentially oncogenic integrations. Some cancers showed
very high ZFERV copy number, well above that seen in
T lymphocytes. We also demonstrate the expression of
retrovirally encoded RNAs by both normal and cancerous D.
rerio T cells, with most malignancies displaying signiﬁcantly
elevated proviral transcription relative to normal T cells.
Our ﬁndings, and further characterization of this ERV,
will be essential to understanding how this biologically
active retrovirus impacts normal and malignant zebraﬁsh T
lymphocyte biology.
2.MaterialsandMethods
2.1. Zebraﬁsh Lines and Care. Adult ﬁsh from ﬁve D. rerio
lines were analyzed: normal WIK strain lck::EGFP ﬁsh [12],
the ENU mutant lines hulk, shrek,a n doscar the grouch
(hlk, srk, otg; all WIK background) [6], and rag2::MYC-
ER × lck::EGFP ﬁsh (nacre × WIK hybrid) [5]. Fish were
housed using standard conditions (28.5◦C, 14hr. light/10hr.
dark circadian cycle) in a colony at the University of Utah’s
zebraﬁsh core facility. For examinations under ﬂuorescent
microscopy, ﬁsh were anesthetized with 0.02% tricaine
methanesulfonate (MS222) and euthanized with ice water
prior to dissections. Animals were handled according to NIH
guidelines, under an approved protocol (IACUC #08-08005)
by the University of Utah Animal Care and Use Committee.
2.2. Dissections and Fluorescence-Activated Cell Sorting
(FACS). Zebraﬁsh thymi and GFP+ tumors were dissected,
with preparation of single cell suspensions and FACS per-
formed as described previously [6]. BD FACSVantage and
FACSAria II SORP (Becton Dickson) instruments were used
for FACS. GFP intensity and side- and forward-scatter were
gating parameters for GFP+ lymphocyte collections.
2.3. Nucleic Acid Puriﬁcations. Genomic DNA for aCGH and
qPCR was extracted from FACS-puriﬁed GFP+ T cells and
matched tailﬁn tissue using the DNeasy Blood and Tissue
Kit (Qiagen) as described previously [8]. Total RNA for qRT-
PCRassayswasextractedfromFACS-puriﬁedTlymphocytes
and T cell cancers with Trizol (Invitrogen) or the RNeasy
Mini-Kit (Qiagen) according to manufacturer instructions.
RNA samples were treated with RNase-Free DNase (Qiagen)
according to manufacturer instructions prior to qRT-PCR.
2.4. Array Comparative Genomic Hybridization (aCGH).
Genomic DNA was labeled with the BioPrime Labeling Kit
(Invitrogen), puriﬁed, quantiﬁed, and hybridized to Zv6-
based Zebraﬁsh Genomic Arrays (NimbleGen) as reported
previously [8]. Arrays were analyzed using the G2565CA
Microarray Scanner System with SureScan High Resolution
Technology (Agilent) and normalized using Agilent Feature
Extraction software. Copy-number analysis was conducted
using the Rank Segmentation algorithm with Nexus Copy
Number 5.0 software (BioDiscovery). Detailed descriptions
of the aCGH methods used and copy number analyses
performed are available in the supplemental sections of the
report by Rudner et al. [8].
2.5. Quantitative Polymerase Chain Reactions (qPCR). A
LightCycler CFX96 (Bio-Rad) was used for qPCR assays.
B r i e ﬂ y ,I QS Y B RG r e e nS u p e r m i x( B i o - R a d )w a su s e dt o
amplify genomic DNA from various tissue types. Pooled
thymocyte DNA (our limiting sample) was spectrophoto-
metrically quantiﬁed and then diluted 1:100 for use in
qPCR. DNA from tailﬁn tissue and GFP+ tumor cells were
diluted to identical concentrations, with 2μLo fe a c hD N A
used in reactions with total volumes of 25μL, and other
components added according to manufacturer instructions.
All reactions were performed in triplicate. SYBR Green
signals were used to derive estimates of relative ZFERV copy
number. Since true ZFERV copy number is unknown, values
werearbitrarilynormalizedto1copy/haploidgenome.Thus,
a ZFERV relative copy number equal to 3 indicates three
times as many ZFERV copies/genome (e.g., if germline copy
number = 3 copies/haploid genome, ZFERV relative copy
number = 3 indicates 9 copies/haploid genome). All qPCR
results with pol and env were normalized to elf2a,p r e s e n t
in 1 copy/D. rerio haploid genome. Primers and reaction
conditions were as follows:
Forward pol primer: CGC-CCC-ACA-CAT-CAC-
ATA
Reverse pol primer: CAA-CCA-TCA-CAG-AAC-
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Forward env primer: ATG-TTT-GGG-GAA-TGG-
AAG-G
Reverse env primer: TTT-GAT-AAG-GAG-GTG-
GGT-TTT
Forward elf2a primer: TGG-AGG-TGG-AGG-TGA-
GAA-CT
Reverse elf2a primer: GAG-TGG-TTG-TGT-AAG-
CAT-TTC-G
Denaturation: 95◦C × 3m i n u t e s
40 cycles:
95◦C × 10 seconds
59◦C × 40 seconds
Melt curve analysis—55◦C–95◦C.
2.6. Quantitative Reverse Transcription Polymerase Chain
Reactions (qRT-PCR). Total RNA (200ng/sample) from
FACS-puriﬁed normal and malignant T cells was assayed
with the iScript One-step RT-PCR Kit with SYBR Green
(Bio-Rad) using the aforementioned equipment. Reactions
were run in triplicate. Results with pol and env were normal-
ized to elf2a, assayed in parallel qRT-PCRs. Expression fold
changes were calculated by the 2−ΔΔCt method. Primers and
reaction conditions were as follows:
Forward pol primer: CAG-CAC-AAA-CGA-AAA-
TGG-TCT
Reverse pol primer: TGG-CTC-CTC-AGT-GTC-
TCC-TT
Forward env primer: AGA-GGG-AAA-GGA-TGG-
GAT-GT
Reverse env primer: TGT-TGG-ATG-TGG-TCT-
GGT-CT
Forward elf2a primer: ATG-AGA-CAA-TGG-GGA-
GAG-CA
Reverse elf2a primer: GGA-TGC-GGC-TGG-AGT-
TTC
Denaturation: 95◦C × 5m i n u t e s
40 cycles:
95◦C × 10 seconds
52◦C × 10 seconds
72◦C × 30 seconds
Melt curve analysis—55◦C–95◦C.
2.7. Statistical Analyses. The student’s t-test was used to
compare diﬀerences in genomic relative copy number or fold
changes in RNA expression. P values < 0.05 were considered
signiﬁcant.
3. Results and Discussion
We previously performed an ENU-mutagenesis phenotypic
screen designed to identify abnormal T-cell phenotypes.
Our screen resulted in the discovery of three D. rerio lines
(srk, hlk, otg) prone to T-cell malignancies, speciﬁcally T-
A L La n dT - L B L[ 6]. To investigate non-germline acquired
genetic changes occurring in these cancers, we used aCGH
to compare DNA of neoplastic and normal tissues from
individual ﬁsh of each of these lines. These experiments
revealed several homologous genes that are commonly
ampliﬁed or deleted in both zebraﬁshand human T-ALL[8].
In those studies, >98% of D. rerio genes with somatically
acquired CNAs also had identiﬁable human counterparts.
However, two non-homologous genomic regions unique
to zebraﬁsh were also particularly interesting. These loci
showed copy number gains in 8/8 zebraﬁsh T-cell cancer
genomes relative to DNA of nonmalignant tissues from the
same animals (Figure 1). Notably, T-ALLs from all three
lines (3/3 srk,3 / 3hlk,2 / 2otg) exhibited copy number
gains in both regions, establishing these acquired genomic
ampliﬁcations as consistent features in T-cell cancers arising
from diﬀerent genetic backgrounds. Our aCGH experiments
usedaNimbleGenmicroarrayplatformconstructedfromthe
Zv6 genomic assembly. We subsequently discovered that the
probes displaying ampliﬁed signals were mistakenly assigned
to distinct regions on chromosomes 7 and 14 (hybridization
data depicted in Figure 1). However, upon closer inspection
these probes actually derive from a single, approximately
11kb, locus. Intriguingly, this region corresponds to a
genomically integrated retroviral element dubbed ZFERV by
Shen and Steiner, named as such because it is the ﬁrst and
thusfaronlydescribedzebraﬁshendogenousretrovirus[11].
In scrutinizing the six aCGH probe sequences localized
to these two chromosomes, we realized they were in fact
distributed throughout the ZFERV genome (Figure 2).
Collectively, our hybridization results with these 6 probes
provide compelling evidence that the entire ZFERV locus
is undergoing somatic ampliﬁcations in the genomes of
zebraﬁsh T-cell cancers. Because our aCGH data is internally
normalized by comparing each cancer’s DNA to paired
non-malignant tailﬁn DNA from the same ﬁsh, our results
are protected from possible ZFERV copy number variation
(CNV) that might exist between diﬀerent animals. However,
due to ambiguity regarding initial (i.e., germline) ZFERV
copy number in individual ﬁsh, it is impossible to deduce the
absolute number of copies gained by each cancer. Instead,
our ﬁndings are limited to the conclusion that ZFERV has
been ampliﬁed, relative to the original number of ZFERV
copies, in 8/8 T cell malignancies tested. Moreover, because
“normal” ZFERV copy number and genomic locations may
vary between ﬁsh or between strains, thus far, determining
absolute ZFERV copy number prior to oncogenesis has been
challenging.
Reinforcingthecomplexityofthisissue,previous D. rerio
genome builds have displayed ZFERV in multiple locations
on each assembly, and also on several diﬀerent linkage
groups (LG 1, 5, 7, 14, 15, 16, 17, and 22). It is inherently
diﬃcult to accurately map multicopy loci like ZFERV, and4 Advances in Hematology
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Figure 1: Recurrent ampliﬁcations of a small genomic locus in zebraﬁsh T-ALL. Ten kb loci on chromosomes 7 and 14 (Zv6 genomic
assembly) show high-copy gains with multiple probes in these regions (black arrows) of 8/8 D. rerio T-ALL samples tested. Signal intensities
above a “high-copy gain threshold” (upper green line) indicate a greater than 2-fold increase in copy number. Individual probes and their
intensities are depicted as blue dots; areas with 3 adjacent probes above the high-copy gain threshold use green dots to denote those probes.
Seven cancers exhibited high-copy signals for ≥5/6 probes in this region, while srk T-ALL3 had high-copy signals for only 2/6 probes.
this is made even more taxing by its sequence composi-
tion. ZFERV harbors several redundant sequence tracks,
including 5  and 3  long terminal repeats (LTRs) and a
517bp repeat region (RR) containing 9 consecutive repeat
elements (see Figure 2). When compounded with potential
variability resulting from strain-speciﬁc ZFERV integrations,
it is perhaps predictable that ZFERV has not received
deﬁnitive chromosomal map position(s). Consequently, the
c u r r e n tN C B Iz e b r a ﬁ s hg e n o m ea c t u a l l ys u p p r e s s e sZ F E R V
sequences and curates them so they do not appear on the
Zv9 assembly at all.
In the original report describing ZFERV, Shen and
Steiner conducted studies to address some of these questions
concerning copy number and genomic localization: to prove
that ZFERV was integrated into the D. rerio germline, they
tested sperm DNA from several T¨ ubingen (T¨ u) ﬁsh and
veriﬁed an integration site common to each of their genomes
[11].Additionally,usingSouthernblotsofT¨ ugenomicDNA,
they detected 2–4 bands hybridizing to a ZFERV env probe,
implying a maximum of four retroviral copies per haploid
genome [11]. However, not all T¨ u ﬁsh showed identical
hybridization patterns. This could be due to restriction site
polymorphisms in the T¨ u strain but might also suggest that
diﬀerentﬁsh,evenfromthesamestrain,canpossessdiﬀerent
ZFERV copy number and integration sites. Moreover, when
Southern hybridizations with an LTR-based probe were
performed, 8–10 bands were seen. Most—but not all—of
these entities were shared by diﬀerent T¨ u ﬁsh [11]. As with
prior results, this ﬁnding might be attributable to variability
in ZFERV copy number and genomic position between
diﬀerentﬁsh.Anotherinterpretationthatmustbeconsidered
is that homologous LTRs from other related retroviruses
and/or incomplete ZFERV proviral genomes (having ≥1
LTR, but no env) would yield a similar experimental
outcome.
In spite of these uncertainties, our aCGH data remain
convincing as evidence of somatically acquired ZFERV am-
pliﬁcations in D. rerio T-cell cancers. None of our aCGH
probes correspond to LTR sequences, and 5/6 derive from
the retroviral gag, pol,o renv genes (Figure 2). Furthermore,
even if repeat elements had been used in hybridizations,
ourmethodofcomparingneoplastic tonon-malignantDNA
from the same animal is designed to normalize for CNV
discrepancies between diﬀerent ﬁsh. Therefore, we conclude
that zebraﬁsh T-cell malignancies acquire non-germline
ZFERV copies at some point after fertilization, but whether
ampliﬁcations precede and contribute to oncogenesis is
unclear.
Because ZFERV transcription occurs in normal zebraﬁsh
T cells [11], we were curious whether normal D. rerio T
lymphocytes might also have ZFERV copy gains. To deter-
mine if retroviral ampliﬁcations also occur in nonleukemic
T cells, we investigated ZFERV in normal zebraﬁsh T lym-
phocytes. To emulate our aCGH comparisons, we developed
quantitative PCR (qPCR) assays for two ZFERV genomic
regions. Using DNA from cancers with gains identiﬁed by
aCGH, we veriﬁed these assays’ ability to detect ZFERV
copy number gains (data not shown). Next, we employed
these qPCRs of amplicons from the pol and env regions
(locations shown in Figure 2) to test genomic DNA from
tailﬁn tissue and FACS-puriﬁed T cells of wild-type (WT)
adult zebraﬁsh. Thymocytes were obtained from WT WIKAdvances in Hematology 5
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Figure 2: ZFERV Genomic Organization. The ZFERV retrovirus is comprised of two 695bp long terminal repeats (LTRs), a 517bp repeat
region (RR) containing 9 direct repeats, and ORFs for 3 proteins: gag, pol,a n denv [11]. The gag and pol genes share the same reading frame
and are predicted to be translated from one transcript by read-through of a stop codon; env uses a diﬀerent reading frame and is probably a
distinct transcript [11]. aCGH probe sites are shown beneath the ZFERV genome schematic: probes found on Zv6 chromosomes 7 (∗)a n d
14 (#) are dispersed throughout ZFERV. One aCGH probe had sequences corresponding to the RR (##), and has multiple binding sites in this
area. The 5 remaining aCGH probes map to ORFs. Amplicons from qPCR and qRT-PCR assays are also depicted (not shown to scale). The
pol and env qPCR products are 168 and 169bp, respectively; qRT-PCR products are 225bp for pol and 234bp for env.
D. rerio carrying an lck::EGFP transgene [12]. Since the
zebraﬁsh lck promoter is T cell speciﬁc, T lymphocytes from
this line are GFP+. However, unlike ﬁsh with T-ALL or T-
LBL, adult (>6 months of age) WT ﬁsh have signiﬁcantly
fewer T cells (approximately 5 × 104 GFP+ thymocytes/ﬁsh;
our unpublished observations). Consequently, we pooled
thymic tissue from several WT ﬁsh for FACS puriﬁcations.
We then analyzed amplicons from both ZFERV regions to
independently assay copy number diﬀerences.
Tailﬁn DNAs were tested individually or in small groups
to ascertain whether there were appreciable germline CNV
diﬀerences in WIK strain ﬁsh (Figure 3, lanes 1–6 and 8–
10). As seen in these data, qPCR of pol (Figure 3(a)) and
env (Figure 3(b)) show little deviation between ﬁn DNA
from diﬀerent WIK ﬁsh, implying that CNV was minimal in
these strain-related animals (lanes 7 and 11). Because copy
number was so uniform, this further suggests that ZFERV
ampliﬁcation does not occur in ﬁn tissue. Thus, we conclude
thatZFERVstatusinﬁntissuelikelyrepresentstruegermline
copy number, and that this level is relatively stable between
individual ﬁsh.
In contrast, normal T cells pooled from these same WT
ﬁsh showed signiﬁcant ZFERV gains relative to tailﬁn DNA
(Figure 3, lanes 12, 13). On average, WIK T cells had 2- to 3-
fold as many ZFERV copies as matched tail DNA (compare
lane 11 to 14). Since germline copy number is unknown, we
cannot deduce the real number of ZFERV copies in these T
cells.Nonetheless,ifpriordatasuggesting2–4copies/haploid
genome are accurate [11], these results indicate normal T
cells may average up to 12 copies per haploid genome, or 24
copies/diploid T cell. If correct, this would compute to 16
new ZFERV integrations, on average, in each T cell.
BecauseweusedTlymphocytespooledfromseveralWIK
ﬁsh in these studies, we cannot deﬁnitively conclude whether
all animals’ T cells bore evidence of ZFERV ampliﬁcation. It
is possible that only one or a few ﬁsh have ZFERV gains, with
DNA from those ﬁsh skewing the average upward. However,
even in one ﬁsh, T lymphocytes constitute a nonclonal
population. It is possible—perhaps even likely—that ZFERV
copy number varies on a cell-to-cell basis. ZFERV ampliﬁ-
cations may occur in T cells themselves; alternatively, they
might take place earlier along the hematopoietic stem cell/T
cell progenitor diﬀerentiation spectrum. We have not tested
precursor populations, as these are impossible to obtain in
D. rerio owing to the dearth of antibodies to cell surface
receptors. Irrespective of its precise timing, we conclude that
thymocytes acquire additional genomic ZFERV copies at
some point after fertilization, exactly like those detected in
our aCGH analyses of zebraﬁsh T-cell cancers.
Notably, there is precedent proving that ZFERV is active
in zebraﬁsh T cells. This retrovirus was originally discovered
from a thymic cDNA library, after adult D. rerio thymus
had been subtracted against 2-day postfertilization (dpf)
larval ﬁsh, which have not yet developed T lymphocytes
[11]. This study identiﬁed 43 clones hybridizing to only
adult thymic cDNA. Of these, 21 clones also showed thymus-
speciﬁc staining in 7-dpf in situ hybridizations (ISH). After
sequencing, Shen and Steiner recognized that all 21 clones
derived from various segments of the ZFERV genome [11].
So, not only was ZFERV transcribed by both 7-dpf and adult
thymocytes, its expression in these cells was signiﬁcantly
higher than in other tissues by these two methodologies.
Subsequent ISH experiments in 4-dpf, 5-dpf, and 3-month-
old juvenile ﬁsh, as well as Northern blotting of RNA
from adult ﬁsh thymocytes, conﬁrmed these ﬁndings [11].
Together, these prior studies and our own new ﬁndings
demonstrate that ZFERV is highly transcribed by larval and
adult D. rerio thymocytes and that ZFERV ampliﬁcations
occur in the genomes of normal and malignant zebraﬁsh T
cells.
To further expand our understanding of these phenom-
ena, we next compared ZFERV ampliﬁcations in cancer-
prone thymocytes and neoplastic T cells to WT T cells. For
these experiments, we used our qPCR assays to compare
ZFERV copy number in two other T-cell malignancy pre-
disposed lines, hlk and MYC-ER. Both of these lines are
prone to T-LBL and T-ALL, allowing ZFERV quantiﬁcation
of their germlines, their “premalignant” T lymphocytes,6 Advances in Hematology
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Figure 3: ZFERV ampliﬁcations in WT WIK D. rerio Tc e l l s .G e n o m i cD N Af r o m1 5W I Klck::EGFP ﬁsh was analyzed by qPCR of the
ZFERV pol (a) and env (b) genes. White bars depict results from tail DNA of individual ﬁsh (lanes 1–6) or groups of 3 ﬁsh (lanes 8–10).
Black bars show calculated means of 6 singly tested tails (lane 7) or all 15 tails (lane 11). “Tails 7–9” sample (lane 8) was arbitrarily assigned
copy number equal to 1, and this DNA was used as the reference standard for all subsequent qPCRs. T cells pooled from 9 or 6 WT ﬁsh (gray
bars) had 2- to 3-fold gains in ZFERV. Mean copy number was higher in T cells than tailﬁn DNA for the 15 ﬁsh cohort (lane 11 versus 14).
Zebraﬁsh elf2a (1 copy/haploid genome) qPCR was used to normalize pol and env results (not shown). Water-only template controls lacked
detectable product (not shown). Reactions were performed in triplicate, and error bars show standard deviations (env qPCR of tails 2 and 5
had standard deviations too small to be seen).
and their malignant T cells. All MYC transgenic ﬁsh
have hypertrophic thymi, likely reﬂecting abnormal T-cell
proliferation and physiology. In contrast, hlk ﬁsh carry
an unidentiﬁed mutation, display normal-appearing thymi,
and the molecular basis for their cancer predisposition is
unknown. T-ALL or T-LBL aﬄicts roughly 35% of hlk
homozygotes by one year [6], reﬂecting a requirement for
additional mutations to promote malignant transformation
[8]. By comparison, WT lck::EGFP ﬁsh rarely develop T-
cell cancers (<0.1%, our unpublished observations) and
have normal T-cell development and physiology [12]. Thus,
using these samples we could investigate whether normal,
abnormal, and neoplastic T cells all exhibited similar degrees
of ZFERV ampliﬁcation.
As in earlier experiments, we examined tailﬁns from
individual ﬁsh to ascertain ZFERV germline variability. Tails
from single hlk and MYC-ER ﬁsh (Figures 4 and 5,l a n e s3 –
8) demonstrated consistent copy number between animals.
Moreover, both hlk and MYC-ER tails had ZFERV CNV
similar to the WT WIK line (compare lane 1 to other white
bars in Figures 4 and 5). Based on these results, identical for
both the pol and env regions, we conclude that all 3 lines
have approximately equivalent germline copies of ZFERV.
In pooled premalignant T cells (i.e., thymocytes from hlk
and MYC-ER ﬁsh lacking tumors or other non-thymic GFP),
genomic ZFERV was again elevated relative to tailﬁn DNA
from the same ﬁsh (Figures 4 and 5, compare gray bars in
lanes 10-11 to white bars in lanes 3–8). Overall, mean T-cell
ZFERV copy number was roughly 3-fold above germline in
WT, 4-fold higher in hlk, and 5-fold increased in MYC-ER
(compare lane 9 to 12 in both ﬁgures). Since WT, hlk,a n d
MYC-ER thymocytes all showed approximately equivalent
gains, we infer that genomic integration is not appreciably
enhanced in T lymphocytes of either cancer-prone genotype.
Thus, while retroviral ampliﬁcation is clearly a common
feature of all D. rerio T cells, cancer predisposition probably
does not directly originate from increased susceptibility to
ZFERV integration, as these events evidently transpire in
normal T cells regularly. However, it is plausible that cancer
predisposing mutations and ZFERV copy number gains may
cooperate to promote malignant transformation of T cells,
as ampliﬁcations were uniformly present in every T-ALL
sample examined by aCGH.
ToinvestigatehowWTandcancer-proneTcellscompare
to actual neoplasias in the hlk and MYC-ER lines, we also
analyzedmalignanciesfromthesesamegeneticbackgrounds.
We performed pol and env qPCRs on 3 hlk and 5 MYC-ER
ﬁsh, each of which had large thymic tumors and/or extensive
GFP+ disease in extra-thymic areas (Figures 4 and 5). Tail
DNA from these 8 ﬁsh all had similar germline ZFERV
content to previously tested tailﬁn samples (compare lanes
13–15 in Figure 4 and lanes 13–17 in Figure 5 to other white
bars in both ﬁgures).Like hlk Tl ym p h oc yt e s ,hlk cancershad
ZFERVampliﬁcation(Figure4,lanes16–18).However,gains
were similar in magnitude to those seen in hlk premalignant
T cells (compare lane 12 versus 19). In MYC-ER cancers,Advances in Hematology 7
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Figure 4: ZFERV ampliﬁcations in hlk zebraﬁsh. DNA from 6 hlk ﬁsh with normal phenotype and 3 with GFP+ cancers was tested by qPCR
of pol (a) and env (b). White bars show tail DNA of individual normal (lanes 3–8) or T-ALL+ (lanes 13–15) ﬁsh. All were statistically similar
to each other and to WT Tails 7–9 (lane 1). Pooled T cells from hlk ﬁsh without T-ALL (gray bars) had ZFERV gains comparable to normal
WIK T cells (lane 2). Mean copy number was higher in hlk T cells than tails (lane 9 versus 12) in the same animals. Diagonally striped bars
show ampliﬁcations in neoplastic T cells of 3 hlk ﬁsh (lanes 16–18). Mean copy gains were similar in non-malignant and malignant hlk T
cells (lane 12 versus 19). Other details are as described in the legend to Figure 3.
ZFERV gains were also detected (Figure 5, lanes 18–22). As
in hlk, benign and malignant MYC-ER T cells did not show
appreciable copy number diﬀerences (compare lane 12 to
23).
We also tested 2 other malignancies by qPCR. In one WT
lck::EGFP ﬁsh, we noticed a large GFP+ thymic tumor. In
our experience, the spontaneous occurrence of T-cell cancer
in WT ﬁsh is exceedingly rare, so we used this opportunity
to investigate whether ZFERV ampliﬁcation accompanied
this event. Tail DNA indicated this animal had normal
ZFERVgermlinecontent(Figure6,comparelane1versus9),
and cancerous T cells from this ﬁsh showed approximately
5.5-fold higher copy number (lane 10). This degree of
ampliﬁcation is roughly twice that seen in normal WIK T
cells and more closely resembled typical copies in MYC-ER
T cells and cancers (compare lane 10 to lanes 4, 6, and 8).
However, since this result reﬂects only one tumor, no general
conclusions can be drawn about retroviral ampliﬁcation in
the rare cancers of WT ﬁsh. Lastly, in one additional hlk
cancer, we found remarkably high ZFERV levels, showing
25- to 30-fold ampliﬁcation above germline (lanes 11 and
12). This degree of copy number gain is nearly ten times
higherthantheother9T-ALLsweexaminedbyqPCR,orthe
8 tested previously by aCGH. Nonetheless, this infrequent
scenario clearly demonstrates that ZFERV can parasitize the
zebraﬁsh genome in striking fashion, as this cancer likely
harbors as many as 50–100 newly acquired retroviral copies.
Taken together, we conclude that virtually all MYC-
driven, hlk-, srk-, and otg-induced, or even spontaneous
zebraﬁsh T-cell cancers have ZFERV ampliﬁcations. How-
ever, since nearly all benign, cancer-prone, and malignant
T cells show similar genomic levels, the absolute amount of
ZFERV ampliﬁcation does not appear to be an important
oncogenic determinant. This is not surprising, as it is likely
that the site rather than the number of integrations is the
crucial factor. To pursue this premise, one could identify new
loci where ZFERV has integrated into cancer genomes, with
the hypothesis that these might lie near or within proto-
oncogenes or tumor suppressors. We have initiated such
studies, and they are currently in progress. As an adjunct,
we chose to investigate transcription of ZFERV-derived
RNAs. We reasoned that integrations into transcriptionally
permissivegenomicsites mightbeaccompaniedbyincreased
ZFERV RNA expression, perhaps signifying “active” proviral
copies. While these insertions might not denote sites where
oncogenes or tumor suppressor reside, it could serve as a
proxy for ZFERV promoter potency in the genome overall.
If so, this predicts that cancers would have higher ZFERV
transcription than normal T cells and perhaps premalignant
Tl y m p h o c y t e sa sw e l l .
To conduct these studies, we developed quantitative
Reverse Transcription-Polymerase Chain Reactions (qRT-
PCR) of the ZFERV pol and env genes (amplicon locations
shown in Figure 2). As for qPCR, we used pooled normal
T cells from WT WIK ﬁsh as our reference. Recall that
even normal T lymphocytes highly express ZFERV tran-
scripts [11], so these RNAs are already plentiful in the
cells used as our standard. Results for pol and env were
highly reproducible between two pooled T-cell samples from
diﬀerent groups of WT ﬁsh, and this value was arbitrarily
assigned an expression level of 1 (Figure 7,l a n e s1a n d
2). By comparison, pooled pre-cancerous T cells from hlk
ﬁsh exhibited approximately 6-fold and 7-fold enhanced
pol and env transcription, respectively (lane 3, white bar).
Likewise,pooledpremalignantTcellsfromMYC-ERﬁshalso
had higher ZFERV transcripts (lane 9; pol: 9-fold increase,8 Advances in Hematology
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Figure 5: ZFERV ampliﬁcations in MYC-ER zebraﬁsh. Phenotypically normal (n = 6) or T-ALL+ (n = 5) MYC-ER ﬁsh were tested by
qPCR of pol (a) and env (b). White bars display tail DNA from single normal (lanes 3–8) or diseased (lanes 13–17) ﬁsh. MYC-ER tails had
similar copy number to each other (compare lanes 3–8 and 13–17) and to WT Tails 7–9 (lane 1). T cells pooled from groups of 3 normal
MYC-ER ﬁsh (gray bars) showed ZFERV ampliﬁcation; higher gains were seen in MYC-ER than WT T cells (lane 2 versus 12; P values 5.86
× 10−4 for pol,0 . 1 5f o renv). T cells showed 4- to 5-fold higher ZFERV copy than matched tails (lane 9 versus 12). Diagonally hatched bars
depict ampliﬁcations in T-ALL cells from 5 MYC-ER ﬁsh (lanes 18–22). Cancer ZFERV levels were well above paired tails (compare lanes
13–17 to 18–22). Slightly lower gains were seen in cancerous than non-malignant MYC-ER T cells (lane 12 versus 23); this reached statistical
conﬁdence for pol, but not env. Other details are as listed in Figure 3’s legend.
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Figure 6: ZFERV ampliﬁcations in two other D. rerio T-cell cancers. One WT WIK ﬁsh spontaneously developed a GFP+ thymic tumor and
wastestedbyqPCRofpol(a)andenv(b).Averagecopynumbersofothersamplestestedpreviouslyareshownasblackbars.GermlineZFERV
copy number in this ﬁsh (lane 9) was similar to the 15 WIK ﬁsh already examined (lane 1). This tumor showed 5.5-fold ampliﬁcation (lane
10, diagonal bar), similar to non-malignant T cells and cancers from WT, hlk,a n dMYC-ER ﬁsh (lanes 4–8). One other hlk T-ALL exhibited
high-level, 25- to 30-fold gains (lane 12), although its germline copy number (lane 11) was comparable to other ﬁsh (lanes 1–3).
env: 2.5-fold increase). So, while ZFERV genomic ampliﬁ-
cation did not diﬀer impressively between WT and cancer-
prone T cells (3- to 5-fold; Figure 6), expression of retrovi-
r a lt r a n s c r i p t sw a sm o r ep r o n o u n c e di nTc e l l sf r o mb o t h
cancer-prone genotypes.
We also examined T-cell cancers from both lines (n = 10;
4 hlk,6MYC-ER). In hlk malignancies, all 4 cancers (lanes
4–7, gray bars) showed increased pol and env compared to
normal T cells. One cancer (hlk T - A L L4 ;l a n e4 )r e s e m b l e d
premalignant hlk T cells in its transcriptional proﬁle. This
same tumor had also been tested by qPCR and showed
comparable ZFERV ampliﬁcation to non-malignant hlk T
cells (see Figure 4, lanes 12 and 16). So, in this instance, copy
numbermirroredZFERVexpression.ThreeotherhlkcancersAdvances in Hematology 9
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Figure 7: ZFERV gene expression by normal and abnormal D. rerio T cells. Total RNA was tested by qRT-PCR of the ZFERV pol (a) and env
( b )g e n e s .N o r m a lTc e l lR N Ap o o l e df r o mW I Kﬁ s h( n = 16 and 18; lanes 1, 2) were used as control, and the “WIK T cells 16–31” sample
was arbitrarily set to an expression value = 1. Premalignant T lymphocytes from hlk (n = 6) and MYC-ER (n = 3) ﬁsh had higher expression
than WT ﬁsh (white bars; lanes 3, 9), and this higher transcription reached statistical signiﬁcance. Individual cancers from hlk (n = 4; lanes
4–7) and MYC-ER (n = 6; lanes 10–15) ﬁsh are depicted with gray bars. Cancer cells from these ﬁsh invariably showed higher pol and env
transcripts than T cells from WT ﬁsh, and nearly always had elevated RNA expression relative to normal T cells from these same two lines.
Mean expression of pol and env in malignant T cells (black bars; lanes 8, 16) exceeded both WT and premalignant T cell transcript levels.
Two cancers highlighted by asterisks (hlk T-ALL 4, hlk T-ALL 7; lanes 4, 5) were also tested for genomic copy number by qPCR. The hlk
T-ALL 4 cancer had ZFERV copy number similar to hlk premalignant T cells (see Figure 4), and its pol and env expression also resembled
hlk T cells. Cells from the hlk T-ALL 7 sample had high-level genomic ZFERV gains (see Figure 6), and likewise demonstrated dramatically
increased ZFERV transcription.
(Figure 7, lanes 5–7) had greater pol and env transcription
than hlk premalignant T cells, with at least 2-fold increases
in both transcripts. One of these (hlk T-ALL 7; lane 5) had
markedly higher levels, with 13-fold pol upregulation and
7-fold higher env than non-malignant hlk T cells (lane 3).
The hlk T-ALL 7 sample was also analyzed by qPCR and
exhibited high copy gains (Figure 6, lane 12), providing a
second example that correlated genomic copy number to
ZFERV transcriptional activity. Overall, mean transcription
was 5-fold greater for pol a n d3 - f o l dh i g h e rf o renv in hlk
cancers than their pre-cancerous T lymphocytes (compare
lane 3 versus 8), although the hlk T-ALL 7 cancer skews
this result somewhat. That notwithstanding, every hlk cancer
showed ≥4-fold upregulation of both transcripts relative to
WT thymocytes, proving that higher ZFERV expression does
coincide with malignancy.
Similar ﬁndings were also obtained in 6 MYC-ER cancers
(lanes 10–15, gray bars). Although transcript levels varied in
individual cancers, mean pol expression was 2-fold increased
and env was 3-fold higher in all six malignancies compared
to MYC-ER premalignant T cells (compare lane 9 versus 16).
Expressionofpolandenvbythesametumorusuallyfollowed
the same trend. However, some cancers did have discordant
transcription of these two genes. Despite these disparities,
MYC-ER cancers averaged 18- and 7-fold higher pol and
env, respectively, than normal T cells from WT ﬁsh, further
implicating ZFERV in zebraﬁsh T-cell oncogenesis.
Though ZFERV copy number and transcriptional activ-
ity correlated in the two cancers where we evaluated both
genomic and expression data, variation between pol and
env in the same tumor requires another explanation. Unlike
ZFERVgag-pol,whichisthoughttobetranscribedasasingle
RNA, pol and env come from distinct transcripts [11]. Thus,
these genes could be diﬀerentially regulated. In addition,
other factors may impact overall ZFERV transcription.
As noted previously, certain integration sites might foster
retroviral activity. In addition, cancers with very high copy
number might be expected to have commensurate RNA
levels, and our limited data support this. Another potential
factor regulating transcription pertains to normal patterns
of ZFERV expression in T lymphocytes. While it is known
that D. rerio T cells normally make ZFERV RNA ([11]
and this work), it is not known if all T-lineage cells do,
or rather if only some T lymphocyte developmental stages
have active ZFERV. Since T-ALL can exhibit diﬀerentiation
arrests at multiple maturational stages [13, 14], it is possible
that individual cancers with diﬀering arrest points might
also demonstrate diﬀerent ZFERV transcription patterns.
Unfortunately,thelackofantibodyreagentsabletorecognize
zebraﬁsh T cell surface markers currently limit testing of this
latter hypothesis.
Despite these limitations, our ﬁndings indicate that both
genomic ampliﬁcation and transcription of ZFERV may im-
pact normal D. rerio T-cell biology and oncogenesis. In10 Advances in Hematology
particular, our results bolster the notion that new retroviral
integrations could be pathologic on the molecular level. Sta-
bly integrated retroviral elements are common in vertebrate
genomes, with nearly 10% of the human genome comprised
of ERVs or their derivatives [15]. However, most ERVs are
inert due to their accrual of point mutations and partial
deletions. ZFERV is atypical in that its genes apparently
retain unmutated ORFs. Moreover, these genes are robustly
transcribed by D. rerio T cells as veriﬁed by ISH, Northern
blotting,andqRT-PCR([11]andthispaper).Theabundance
of ZFERV RNA in T lymphocytes is perhaps not surprising,
as ZFERV’s LTR was the most potent promoter among
several transcriptional regulatory sequences assayed in a carp
(Cyprinus carpio) epithelial cell line, including the oft-used
CMV promoter [16].
Rather, ZFERV’s apparent T-cell speciﬁcity may be the
more intriguing ﬁnding. Shen and Steiner identiﬁed putative
binding sites for the lymphoid transcription factors Ikaros
and Tcf3 (E47) in the ZFERV LTR, but also for other
factors (FOS/JUN, C/EBP, STAT, NF-κB, and others) that
are more general activators of transcription [11]. Indeed,
thesequencingofZFERV-derivedtranscriptsbyESTprojects
from several other tissue types suggests that non-T-cells may
transcribe ZFERV also [11]. Whether this ﬁnding reﬂects
low-level ZFERV transcription by other cell types, or low-
level T-cell contamination in these tissues, is not clear.
In either case, the atypical persistence of intact ZFERV
ORFs, and their transcriptional activity in zebraﬁsh T cells,
raises the question of whether ZFERV proteins might serve
a functional purpose. Selective pressure would normally
favor mutations disabling a potentially genotoxic retrovirus.
Instead, we hypothesize that ZFERV may in fact serve
some important biologic role, accounting for its paradoxical
maintenance as an active retrovirus in the zebraﬁsh genome.
ZFERV’sapparentabsenceinthegenomesofotherDanio
genera [11] implies that its entry into zebraﬁsh is fairly
recent in evolutionary terms, but ZFERV sequences have
been identiﬁed from several diﬀerent strains, suggesting
that its integration is pervasive in the species. It is not
known whether ZFERV is present in all D. rerio,a n dt o
our knowledge, this question has not been investigated. To
date, the closest relative to ZFERV is an exogenous piscine
retrovirus, SSSV. Curiously, this virus is linked to swim
bladder leiomyosarcomas in Atlantic salmon, and like our
results with ZFERV, these tumors show high copy number
proviral SSSV integration [17].
Besides its close relation to SSSV, ZFERV also shares se-
quence conservation and similar genomic structure with
gammaretroviridae of the murine leukemia virus (MLV)
class [11, 17]. MLV-related retroviruses are known to be
oncogenic by insertional mutagenesis [18], and the determi-
nants governing their preferred integration sites have been
the subject of intense scientiﬁc scrutiny [19–21]. Although
an obvious ZFERV homologue has not been identiﬁed in
humans, other MLV-related sequences have been detected in
human cell lines. However, it appears that these retroviral
sequences may have been acquired by human cells during
xenografting into murine recipients or result from reagent
contamination by murine DNA [22, 23]. In addition, a
long ORF on human chromosome 14 bears high homology
to ZFERV’s env, and upstream sequences contain a short
gag-pol element [24]. So, ZFERV-related retroviruses are
evidently integrated in the human genome as well. Incorpo-
rating all these circumstantial data, it becomes plausible that
ZFERV integrations—like SSSV and MLV—may not only be
oncogenic in zebraﬁsh, but might also have relevance for
human biology in general.
4. Conclusions
Nearly a decade ago, Shen and Steiner discovered a zebraﬁsh
endogenous retrovirus, ZFERV, based on its high transcrip-
tional activity in larval and adult D. rerio thymocytes [11].
Their work suggested that multiple copies of ZFERV existed
in the zebraﬁsh genome, and since that time, the loci where
ZFERVresidesstillhavenotbeendeﬁnitivelyassigned. These
diﬃculties are probably attributable to the fact that this
multicopy locus may vary in copy number and genomic
positioning in diﬀerent ﬁsh. Amidst this backdrop, we have
found that ZFERV copy number is increased still further
in every D. rerio T-cell malignancy we examined from 4
diﬀerent genetic lines.
Somewhat surprisingly, our results demonstrate that
ZFERV ampliﬁcation is not unique to cancerous T cells.
Rather, copy number gains also occur in T lymphocytes
of WT D. rerio, the same cells where ZFERV transcription
was ﬁrst identiﬁed. Moreover, ZFERV copy number appears
to be fairly consistent amongst normal, premalignant, and
malignant T cells (Figure 6, lanes 4–8), although individual
cancers can occasionally show even higher levels of ZFERV
in their genomes. It is possible that individual normal T cells
have similar variability in ZFERV copy number, but this has
not been experimentally addressed.
As seen with genomic ampliﬁcations, ZFERV transcrip-
tion occurs within normal, pre-cancerous, and neoplastic T
cells. Our results suggest that expression of ZFERV RNAs
is higher in cancer samples, but we do not recognize a
consistent trend from one cancer to the next. Nonetheless,
these commonalties between normal and malignant T
lymphocytes imply that ZFERV activation and ampliﬁcation
may be a normal feature of zebraﬁsh T cell biology, with
no pathologic consequence. Still, ZFERV’s abundant tran-
scription,apparentlyfunctionalORFs,andabilitytoundergo
genomic ampliﬁcation all allude to its oncogenic potential.
Compounded with mutations like hlk, srk,a n dotg that
confermalignancypredisposition,ZFERVmayhelppromote
T-cell transformation. Given that the closest phylogenetic
relativesofZFERVareanexogenouspiscineretroviruslinked
to sarcomagenesis and MLV-class retroviruses that are leuke-
mogenic via genomic integration, it is tempting to speculate
that ZFERV may contribute to cellular immortalization by
similar mechanisms.
Certainly, ZFERV integrations in crucial genomic sites
could have transformative properties. For example, integra-
tion within a tumor suppressor gene might render it unable
to generate its normal protein product, thereby ablating
function. Conversely, integrations into the promoter orAdvances in Hematology 11
enhancer regions of proto-oncogenes might augment their
transcription. Since ZFERV appears to be speciﬁcally and
highly expressed by thymocytes, this scenario could be
analogous to the translocation of proto-oncogenes into the
T-cell receptor loci, which are well described in T-ALL
[25, 26]. However, proof of this hypothesis will require
identiﬁcation of somatically acquired ZFERV integrations at
these genomic sites. At this point, the possibility that ZFERV
ampliﬁcations may contribute to T-cell oncogenesis remains
an open question that will require further investigation to
resolve decisively.
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